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 3
1 ABBREVIATIONS 
 
BOLD MRI blood oxygenation level–dependent MRI 
CA contrast agent 
ceMRI contrast enhanced magnetic resonance imaging 
DCE MRI dynamic contrast enhanced MRI 
FID free induction decay 
FOV field of view 
Gd(ABE-DTTA) gadolinium (N-(2-butyryloxyethyl)-N¢-(2-ethyloxyethyl)-N,N¢-
bis[N¢¢,N¢¢-bis(carboxymethyl)acetamido]-1,2-ethanediamine 
IR inversion recovery 
LAD left anterior descending (coronary artery) 
MP myocardial perfusion 
MRI magnetic resonance imaging 
MRS magnetic resonance spectroscopy 
NI neoplastic index 
NIv percent neoplastic index 
NMRD Nuclear Magnetic Resonance Dispersion  
NV neoplastic volume 
PC prostate cancer 
PIN prostate intraepithelial neoplasia 
PM perfusion map 
PPM percent perfusion map 
PSA prostate specific antigen 
R1 longitudinal relaxation rate 
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R1v R1 measured in any given voxel 
ROI region of interest 
SI signal intensity 
SIE signal intensity enhancement 
T1 longitudinal relaxation time 
T2 transverse relaxation time 
TI inversion time 
TRAMP TRAnsgenic Mouse Prostate adenocarcinoma 
v voxel 
VBM virtual biopsy map 
Vv voxel volume 
WD well defined adenocarcinoma 
WM wall motion 
WT wall thickening 
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2 INTRODUCTION 
 
2.1 CONTRAST AGENTS AND THEIR IMPORTANCE 
MRI signal intensity is principally determined by proton relaxation rates (1/T1 
and 1/T2). Thus, it provides the most useful clinical information when the relaxation 
rates are sufficiently different in healthy vs. diseased tissue. Unfortunately, often there 
are no sufficient intrinsic differences between the relaxation rates of healthy and 
diseased tissues. Paramagnetic metal ions, i.e. metal ions that possess unpaired 
electrons can enhance MRI signal intensity. Gadolinium (Gd3+), one of the 
paramagnetic lanthanide metal ions, induces the largest relaxation rate enhancement. 
This enhancement is partially mediated by the direct interaction of the proton spins of 
water molecules in the inner coordination sphere of the paramagnetic metal ion (1,2).  
The solubility of free lanthanide aquo-ions at physiological pH is limited. 
Also, lanthanide, aguo-ions are toxic, inducing cell apoptosis, probably due their 
effects on mitochondrial membranes (3). Organic chelator molecules with negatively 
charged carboxylate groups can form nontoxic and soluble complexes with 
Gadolinium. Such complexes are used as MRI contrast agents. Since contrast agents 
are distributed in body tissue by the blood circulation, differentially between healthy 
vs. diseased tissue, they can generate relaxation rate differences between the former 
and the latter, consequently effecting functional enhancement of contrast in MRI 
images.   
 
2.2 SIGNIFICANCE OF R1 MEASUREMENT 
To date, most of the MRI measurements in the clinic have been based on 
signal intensity (SI) images. In contrast enhanced MRI (ceMRI) the images show 
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tissue differentiation, when they do, on the basis of signal intensity enhancement 
(SIE). SIE in ceMRI is dependent on contrast agent concentration in the tissue volume 
element (voxel) represented by the image area in question, but not in a linear fashion. 
SI is not an intrinsic parameter, rather it is also dependent on the pulse sequence and 
acquisition parameters used. Another confounding factor is the inhomogeneity caused 
by the MRI coil, artificially imparting varying SIs to different parts of the prostate 
depending on their relative position to the coil. The intrinsic physical parameter which 
is enhanced in linear proportion with contrast agent concentration is the paramagnetic 
∆R1 (longitudinal relaxation rate enhancement), induced by a contrast agent.(4) The 
R1 measurement, in the presence of a proper contrast agent, therefore, is not only a 
quantitative but a reproducible method to detect pathomorphologies. 
 
2.3 CLINICAL APPLICATIONS 
 Contrast enhanced MRI is an important clinical tool in the management of 
patients with cardiac diseases. It allows clinicians to assess morphologic and 
physiologic myocardial characteristics in the same imaging session. Our results 
suggest that R1 mapping, eliminating the above detailed factors, may provide 
quantitative, reproducible information that can be used to follow up patients with 
myocardial perfusion defects.  
 It is highly desired to develop a non-invasive diagnostic tool to detect prostate 
cancer (PC) in its early phase. The presently used diagnostic methods (PSA, needle 
biopsy, etc) including DCE MRI, can only be used in the developed phase of PC. 
With our method, in the presence of Gd(ABE-DTTA), it was possible to 
quantitatively determine the volume of neoplastic mass in the prostate of TRAMP 
mice in the early, PIN phases. 
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3 AIMS 
 
3.1 To determine that our contrast agent Gd(ABE-DTTA) has a signal 
enhancement capability in the entire magnetic field range we are planning to carry out 
our experiments 
 
3.2 To determine whether R1 mapping method is capable to provide more 
information than signal intensity MRI images. To investigate this question we will use 
R1 mapping in a canine ischemia-reperfusion model. Addition to that, R1 mapping 
will be carried out in a pixel-by-pixel manner, providing the highest possible 
resolution of the actual MRI instrument used in the experiment. 
 
3.3 To determine whether R1 mapping can provide detailed information similarly 
to the myocardial ischemia model, in more than one pathomorphologies, namely, in a 
mouse model of the prostatic neoplasia. 
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4 THE UNIQUE R1 CHARACTERICTICS OF GD(ABE-DTTA) 
 
4.1 INTRODUCTION 
The agent Gd-ABE-DTTA (Fig1) has been developed in our laboratory (5).  
 
Figure 1. The molecular scheme of the (ABE-DTTA) ligand. 
 
In a canine model of acute ischemic underperfusion, we have used Gd(ABE-
DTTA) successfully to detect ischemic defects in the myocardium not only at the 
extreme limit (100% left anterior descending (LAD) coronary artery occlusion) but 
also in partially underperfused myocardial experimental models (5,6). In recent 
studies, we have also used it to detect myocardial infarction (7). It has shown no 
deleterious physiological effects at the level of the MRI-effective dose in the canine 
model (8). The magnetic field dependence of the longitudinal relaxivity of this agent, 
particularly at high and very high fields (3-14 T) showed unique characteristics.  
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Thus for instance, MRI, enhanced by an appropriate contrast agent, makes 
possible the early and non-invasive detection of myocardial tissue underperfusion (9) 
(10) (11) (6).  
Long Half Life in Blood and Tissue 
 According to our earlier results, Gd(ABE-DTTA) has a uniquely long life time 
in blood and tissues that makes often time consuming R1 assessment possible. 
 
4.2 MATERIALS and METHODS 
Gd(ABE-DTTA) was synthesized, and sample preparation was carried out, as 
described by Saab-Ismail et al [15]. Solutions of 1:1 Gd : ABE-DTTA and 0.7:0.7 Ca : 
ABE-DTTA were mixed to obtain a 10 mM (per Gd complex) stock. An amount of 
this stock was diluted to prepare a 0.1 mL (0.5 mM) sample. This sample was placed 
in a 1.5 mm O.D. tube inserted coaxially within a 5 mm O.D. NMR tube which 
contained CD3Cl for locking purposes when a spectrometer was used to determine 
relaxivity. For measurements carried out on MRI scanners, a phantom was created 
with three vials, each containing 0.5 mM Gd(ABE-DTTA). The interior of the 
phantom around the vials was filled up with agarose.  
All measurements, including the NMRD measurement, were carried out on 20 
Cº. 
In the range 0.0002-1.0T, the field dependence of the longitudinal relaxivity of 
Gd(ABE-DTTA) was assessed with NMRD as detailed by Koenig and Brown [18]. 
At field strengths above 1T a variety of single-field MRI instruments (1.5T GE CVI 
System, Bruker Biospec 4.7T) and NMR spectrometers (Bruker ARX 300, Bruker 
AM 360, Bruker DRX 400, Bruker DRX 500, Bruker DRX 600) were used.  
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On the 1.5T GE CVI System a segmented, inversion-recovery, fast-gradient-
echo sequence was used to generate images with varying inversion-times. The 
imaging parameters were: FOV=300mm, image-matrix=256x256, slice-
thickness=10mm, flip-angle=25°, echo-time (TE) = 3.32ms, views-per-segment=16, 
recycle-time(TR)= 3-5000ms (depending on the heart rate of a volunteer).  
On the Bruker Biopac 4.7T MRI scanner a multi-slice multi-echo (msme) 
inversion recovery (IR) sequence was used for to acquire T1 values with the 
following parameters: FOV: 5 cm, matrix: 128·128, voxel size: 
0.39mm·0.39mm·2mm (slice thickness), number of slices: 1, recycle time was 
3000ms.  
On the NMR spectrometers an inversion recovery sequence was used. The 
sequence parameters and magnetic field strength along with the inversion delay times 
used on the individual instruments are listed in Table 1.  
In the experiments using an NMR spectrometer the R1 values were calculated from 
the signal intensities by the WINNMR software running on the individual NMR 
instrument using the Equation 1.  
I(t)=I(0)+A·exp(-τ/T1)      (1) 
where I(t) is the measured intensity and τ is the interpulse delay time. I(0), A 
and T1 were the variable parameters of the three parameter curve fitting. In the 
experiments carried out on MRI instruments, the images, acquired with different TIs, 
were exported to a PC computer as image stacks. They were reformatted using ImageJ 
(Wayne Rasband, NIH). Regions of interest were determined in the image stacks and 
the signal intensity value series were exported to Origin 6.1. 
 11
 
  
Since these MR images are magnitude images, the polarity of the signal 
intensity values acquired with TIs less than the τ0 value, had to be changed by the 
observer. Calculations were carried out in Origin 6.1, using Equation 1 for curve-
fitting.  
 
The relaxation rate enhancement, ∆R1, induced by the contrast agent, was obtained 
from  
∆R1=1/ T1 (obs)–1/ T1 (o)    (2) 
Table 1 
 
Inversion Delay Times Used 
 
              
System GE CVI System 
Bruker 
Biospec 
4.7 
Bruker 
ARX 300 
Bruker AM 
360 
Bruker 
DRX 400 
Bruker 
DRX 500 
Bruker 
DRX 600 
Field 
Strength (T) 1.5 4.7 7.1 8.5 9.4 12 14 
Operating 
System GE OS 8.1 3.1 
XWINNMR 
2.5 
XWINNMR 
2.5 
XWINNMR 
2.5 
XWINNMR 
3.5 
XWINNMR 
3.5 
τ (ms) 35 10 1 0.5 1 0.1 0.1 
 40 20 2 1 2 1 1 
 50 30 4 100 4 5 5 
 60 50 6.5 25 6.5 10 10 
 70 70 10 50 10 30 30 
 80 90 20 200 20 60 60 
 90 100 40 500 40 120 120 
 100 150 65 1000 65 250 250 
 110 200 100 1500 100 500 500 
 120 300 200 3000 200 1000 1000 
 130 600 400  400 4000 4000 
 140 1000 650  650 10000 10000 
 160  1000  1000   
 180  1500  1500   
 220  2000  2000   
 260       
 280       
 300       
 600       
 1100       
 
Table 1 
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where T1 (obs) was the observed water proton relaxation time in a solution with the 
contrast agent, and T1 (o) was the relaxation time of pure water. In turn, the relaxivity 
r1 was calculated from 
r1=∆·R1/c      (3) 
where c was the concentration (in mM) of the contrast agent.  
 
4.3 RESULTS 
In Figure 2, relaxivity values measured on the NMRD machine (Fig. 2A) and 
seven different single-field instruments (Fig. 2B) are plotted as a function of magnetic 
field strength. Similarly to other contrast agents, GD(ABE-DTTA) (molecular 
weight=760) shows its maximum relaxivity at magnetic field strengths less than 0.01 
T, with a high relaxivity value, above 30 s-1mM-1, unusual for a small molecular 
weight agent, and which is only found with macromolecular complexes (67), (68).  
Its relaxivity reaches a local minimum (~19 s-1mM-1) around 0.2-0.3 T (Fig. 
2A). In distinction from the typical agents presently used in the clinic, its relaxivity 
increases with field strength above this point, reaches a local maximum around 5T 
(Fig 2B), and starts decreasing. Nevertheless, even at 8.5 T it is not lower than its 
relaxivity at 1.5 T.  
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Figure 2 Field Dependecy Profile of the longitudinal relaxivity of Gd(DTPA) and 
Gd(ABE-DTTA) Figure 2 (A) The relaxivities (■) of 0.5 mM aqueous solutions of
Gd(ABE-DTTA) and of Gd(DTPA) (∆) acquired with NMRD as a function of magnetic
field strength. The Gd(DTPA) NMRD data were adapted from Kellar et al. (70). The 
measurements of Gd(ABE-DTTA) were carried out at 20 ºC whereas the measurements
of Gd(DTPA) were carried out at 25 ºC. Figure 2 (B) The relaxivity at 20 ºC of Gd(ABE-
DTTA) (■) (n=12) and Gd(DTPA) carried out on a series of single field MRI and NMR
instruments detailed in Table 1 as a function of magnetic field strength. The 4.7T
datapoint for Gd(DTPA) (∆), was adapted from Mikawa et al. (71). This study was 
carried out at 25 ºC.  
 
At the most widespread magnetic field presently used in clinical practice, 1.5 
T, the relaxivity was 21.5 s-1mM-1, a value considerably larger than that of presently 
used contrast agents. As the field increases, the relaxivity of Gd(ABE-DTTA) further 
increases, reaching a peak of almost 24 s-1mM-1 in the vicinity of 3T. It is noteworthy 
that even around 10T, the relaxivity is still at the considerably high level of 18.5 s-
1mM-1. The relaxivity values measured on separate instruments, and shown in Figure 
2B, are listed in Table 2.  
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Table 2. The relaxivity values of Gd(ABE-DTTA) measured on MRI and NMR 
instruments are shown along with corresponding field strength/proton Larmour 
frequency. 
 
Relaxivity Values 
 
Field 
Strenth  
(T) 
1H Larmour 
Frequency 
(MHz) 
Relaxivity 
 
(mM-1s-1) 
Standard 
Deviation 
 
1.5 64 21.07 ±0.97 
3 128 23.96 ±0.17 
4.7 200 22.83 ±1.21 
7.1 300 20.71 ±0.62 
8.5 360 20.24 ±0.34 
9.4 400 18.64 ±0.41 
12 500 16.10 ±0.50 
14 600 14.84 ±0.46 
  
 
 
4.4 CONCLUSIONS 
To emphasize the different field dependency profile of the Gd(ABE-DTTA) 
relaxivity compared to that of Gd(DTPA), both are shown in Figures 2A and 2B, with 
the Gd(DTPA) data adapted from Kellar et al (70) (Figure 2A) and Mikawa et al (71) 
(Figure 2B). The field dependence of the relaxivity of Gd3+ chelates is governed by 
numerous factors having complex relationships with each other, namely the inner 
coordination environment of the Gd3+ ions and the number of water molecules 
surrounding the Gd3+ in the inner sphere ; the field dependent electronic relaxation 
time of the unpaired electron spins (τS) of the Gd3+ magnetic moment, with low field 
limit (τSO),; the diffusional correlation time (τV) that describes the dependence of τs on 
magnetic the static field; the average distance between the Gd3+ and the water 
molecules in the inner sphere; the proton residence time (τM) of the coordinated water 
molecules, the diffusional time (τD) of a solvent water molecule in the outer sphere; 
and most likely the rotational correlation time of the Gd-chelate (72). The role of the 
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second hydration shell can be important when the ligand exchange in the inner sphere 
is slow (68). The field dependence profile of Gd(ABE-DTTA) looks qualitatively 
similar to those of the water solutions of protein-bound paramagnetic ions, for 
example Mn-concavalin A and Cu-SOD, reported by Koenig et al (67), (68). These 
authors interpreted the local maximum seen in the high field range for these 
complexes in terms of the relaxation properties of the electron spins of the 
paramagnetic ions, which manifest themselves in the proton relaxation through their 
contribution to the correlation time (67). The rotational correlation time (τR) is an 
additional important factor leading to a local maximum in relaxivity of some slowly-
rotating Gd3+ complexes in the high field range (73). Toth et al investigated the 
NMRD profiles of gadofullerenes and also found a local relaxivity maximum in the 
high field range.  
The field dependency profile of the Gd(ABE-DTTA) relaxivity is similar to 
the above mentioned high molecular weight complexes. Thus one would expect the 
environment of its Gd3+ ion to be similar to those of such slowly-rotating complexes. 
As Gd(ABE-DTTA) is of the relatively low molecular weight of 760 Dalton, its 
relaxivity profile is perplexing. We suggest that the chemical structure of the ABE-
DTTA ligand (Fig. 1), with its lipophylic butyryl chain, may provide the explanation. 
Such lipophylic chains may lead to micelle formation, increasing the effective radius 
of the aggregate complex, and leading to the observed field dependency profile. 
Irrespective of the exact mechanism of its relaxivity, considering the historic trend of 
the development of clinical MRI instruments that operate at increasingly higher 
magnetic fields, Gd(ABE-DTTA) could become the contrast agent of choice in cases 
where high field imaging would be particularly useful. 
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5 IN VIVO R1-ENHANCEMENT MAPPING OF CANINE 
MYOCARDIUM USING CEMRI WITH GD(ABE-DTTA) IN AN ACUTE 
ISCHEMIA-REPERFUSION MODEL. 
 
 
5.1 INTRODUCTION 
Ischemic heart disease remains the leading cause of death in western societies 
(12). A non-invasive imaging method to visualize acute myocardial ischemia is highly 
desirable (13-15). The techniques currently used, contrast-enhanced cardiac 
ultrasound and technetium-99m-tetrofosmin Single-Photon Emission Computed 
Tomographic (SPECT) imaging, along with thallium-201 myocardial tomography, are 
not optimal for accurate localization and, more importantly, for quantitative 
determination of myocardial underperfusion (16). Presently, coronary angiography 
provides the most accurate information for the differential diagnosis of acute 
myocardial ischemia. This method, however, carries significant risks and is not 
repeatable as many times and as often as MRI is (17,18). Contrast-enhanced MRI 
(ceMRI) can visualize myocardial ischemia with less risk (19,20), but the present 
techniques of cardiac ceMRI could be improved on in the area of spatial resolution 
and coverage. In this work we present results obtained by R1 mapping, which in 
conjunction with a long tissue-lifetime contrast agent (CA), Gd(ABE-DTTA), 
provides quantitative pixel-by-pixel information on myocardial underperfusion. 
In differential diagnosis of acute myocardial ischemia, cardiac MRI has played 
an increasingly important role in the visualization of perfusion abnormalities. Using 
BOLD MRI, myocardial ischemia can be detected without using contrast agents (21). 
However, to precisely delineate the ischemic area in the myocardium, the use of MRI 
contrast agents is required (22-24). Based on the distribution differences of a CA 
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between healthy and ischemic regions, ceMRI using gradient echo sequences should 
be able to detect and accurately assess myocardial underperfusion.  
McNamara et al. used Gd-DTPA to detect myocardial ischemia in a canine 
heart model(25).  Gd-DTPA has since remained the most frequently used MRI 
contrast agent for the detection of acute myocardial ischemia in clinical practice (26), 
although some investigators have used other agents in their experimental and human 
studies (27-32). 
MRI contrast agents display wash-in and wash-out kinetics that reflect 
myocardial perfusion abnormalities (33). The application of a first-pass technique to 
detect myocardial ischemia in a rat heart model was reported by Atkinson et al. (34). 
The same authors also visualized myocardial ischemia in patients with coronary 
disease by first pass kinetics using Gd-DTPA (35). To date, this is the best MRI 
technique to detect myocardial perfusion (35). First pass techniques, however, are not 
optimal in spatial resolution and coverage due to short duration of contrast.  
The signal intensity enhancement (SIE) is dependent on CA concentration in 
the myocardial volume element represented by the corresponding image area, but not 
in a linear fashion. SIE is not an intrinsic parameter, but is rather dependent on the 
pulse sequence and the acquisition parameters used. The intrinsic physical parameter 
which is enhanced in linear proportion with CA concentration is the paramagnetic 
relaxation rate enhancement, ∆R1, which is the difference between the inverse T1 in 
presence versus absence of CA. Using ∆R1 for the determination of regional CA 
concentration liberates this determination from dependence on extraneous 
experimental factors (field inhomogenities, preparation pulse errors, saturation, coil 
effect, etc.). The ∆R1 obtained from an ROI that represents a given myocardial 
volume element actually represents the CA concentration integrated over that volume 
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element, because the R1 values, contrary to those of other parameters, are additive. 
Thus, a three dimensional (3D) ∆R1 map of the heart in ceMRI is a faithful 
representation of CA distribution with a spatial resolution down to the voxel-by-voxel 
level. 
To benefit most from ceMRI, several techniques were developed to investigate 
myocardial perfusion defects (36) and pathologies in brain (37). First-pass, the 
commonly used technique to detect myocardial perfusion defects in patients, was first 
reported in 1991 (35). The accuracy of perfusion detection with this method, however, 
is limited since it utilizes MRI signal intensities. Since the signal intensity of a given 
pixel in an MRI image may be distorted by the factors detailed above, a signal-
intensity-based image of the myocardium following CA administration may provide 
inaccurate quantitative information about the location and severity of myocardial 
underperfusion. Thus an R1-map-based approach would be preferable. Unfortunately, 
however, with MRI instruments presently used in the clinic, the acquisition of images 
using inversion recovery (IR) for a typical R1 map currently requires 15 minutes of 
scanning time per tomographic slice. Thus, the myocardial life-time of CAs presently 
used in the clinic is too short for obtaining a R1 map of the left ventricle (LV) with 
IR. To solve this problem, we have introduced an agent that remains in tissue long 
enough to allow the generation of a R1 map. 
We had previously developed Gd(BME-DTTA), a tissue-persistent myocardial 
CA. Subsequently, we successfully applied it in a ferret myocardial ischemia model 
(38). Due to its relatively long life-time in the myocardium, the contrast between the 
ischemic and non-ischemic regions remained significant during the entire 30-minute 
ischemic period. Our present, related agent, Gd(ABE-DTTA) (5) (Fig. 1), has retained 
the MRI qualities of Gd(BME-DTTA), but it is preferable over the latter due to its 
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improved water solubility. It has been successfully used in our previous studies to 
detect myocardial underperfusion (39), (40). Its relatively long lifetime in the 
myocardium allows its use for R1 mapping of the entire LV. 
 
5.2 MATERIALS and METHODS 
Canine Preparation 
Eleven male mongrel dogs weighing 17-19 kg were used in our study. An 
AcqKnowledge v3.7.2 software running on a Toshiba notebook PC, connected to a 
MP100A (Biopac Systems Inc., CA) were used to record ECG and pressure. 
Anesthesia was initiated with an initial I.V. bolus of sodium pentobarbital (25mg/kg). 
Dogs were intubated and mechanically ventilated. Body temperature was maintained. 
An I.V. line was inserted to administer infusion and Pentobarbital. Both femoral 
arteries were cannulated to obtain arterial blood samples during microsphere 
injections and to monitor blood pressure. Blood pressure and ECG were continuously 
recorded. A left side thoracotomy was performed. A 1 cm long section of the left 
ascending coronary artery (LAD) was isolated from its bed. A silk tie was placed 
around the LAD to allow occlusion during the ischemia. The aperture of the 
thoracotomy was closed to restore roughly a normal anatomical situation. To ascertain 
whether the size of the ischemic region was large enough, a 20 second zero-flow 
ischemia test was performed, monitored by ECG.  
Experimental Protocol 
Control short axis MRI images were acquired, microspheres of the first color 
were injected and a blood sample was taken. Subsequently, zero-flow ischemia was 
created by pulling the ligature tight and the contrast agent was injected. At that time, 
microspheres of the second color were injected, a blood sample was taken and from 
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the tenth minute throughout the thirtieth minute of the ischemic period cine and IR 
MRI images were collected. At the end of the thirty minute period of ischemia, the 
LAD ligature was removed to allow forty minutes of reperfusion. Microspheres of the 
third color were injected in the sixth minute of the reperfusion period and a blood 
sample and MRI images were taken. At the end of the reperfusion period the animal 
was euthanized. In Figure 3 the time line of our experimental protocol is illustrated 
(Fig.3). 
 
 
Figure 3 Timeline of the experimental protocol. Left anterior descending coronary artery: 
LAD, inversion recovery (IR), inversion time (TI). 
CONTROL 
 
Treatment        Normal flow in LAD 
Blue microspheres           
administered 
 
 
Duration      40 min 
 
MRI     Long and short axis cine  
Sequences      images and IR images  
    w/ various TIs acquired 
 
 
ISCHEMIA 
 
Zero flow in LAD 
5th minute: Lemon 
microspheres 
administered 
 
30 min 
 
From 10th to 30th    
minutes:  
Long and short        
axis cine images 
and IR images w/ 
various TIs 
acquired 
REPERFUSION 
 
Post-ischemic flow in LAD 
5th minute: Eosin  
microspheres 
administered 
 
40 min 
 
From 10th to 40th 
minutes:  
Long and short axis cine 
images and IR images w/ 
various TIs acquired 
 
 
 
Analysis of Microsphere Perfusion  
The heart was excised, washed, and bread sliced according to the anatomical 
orientation of the short axis MRI images (see below). Each slice was cut into 8 or 16 
pieces (depending on the mass of the actual slice) of approximately 1 gram each. Each 
tissue sample was placed individually in a test tube that contained 1M KOH for 
digestion at 60 °C for 12 hours. The blood samples, however, were digested by 2M 
KOH. Further processing of tissue and blood samples was carried out as described by 
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Simor et al (38) to calculate myocardial perfusion determined by colored 
microspheres (MP). 
Contrast Agent 
Agent Preparation:  
Gd(ABE-DTTA) (Figure 1) was synthesized, and sample preparation was 
carried out as described by Saab at al. Each injectable sample of Gd(ABE-DTTA) was 
prepared by mixing solutions of Gd(ABE-DTTA) and Ca(ABE-DTTA) in a 10:3 
ratio. For quality control, relaxivity of each such sample was measured, and a 
relaxivity of 16.2 sec-1 ·mM-1 (pH 6.4; 20 °C) was routinely obtained.  
Determination of Relaxivity:  This determination was carried out for each injectible 
sample of CA to maintain quality control. The IR method was used to measure T1.  A 
180 degree preparation pulse was followed by a variable delay.  The magnetization 
then was sampled by a second pulse and acquisition of the resulting free induction 
decay signal was carried out.  Magnetization Mτ for any interpulse delay time τ is 
given by the equation:  
   Mτ = Meq(l-A-R1·τ)     (Eq 1) 
where Meq, and R1 are the magnetization at equilibrium and the relaxation rate (R1 = 
l/T1), respectively.  A is a constant dependent on the quality of the 180 degree pulse 
and the extent of signal saturation.  Under ideal conditions, A = 2.0.  For a series of 
delay times τ, FID intensities, or resonance intensities when Fourier Transformation is 
done, are generated and the data are fit to a curve described by Equation 1. A 
three-parameter, no-constraint fit is carried out and the R1, i.e., the relaxation rate, is 
obtained from the best fit. These measurements were carried out on an Avance (360 
MHz, 8.5T) Bruker NMR spectrometer. For each sample, 1/T1 is calculated from 
three consecutive T1 measurements. 
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MRI  
Slice Orientations 
A 7 slice short axis image grid was positioned on the end diastolic image of a 
four chamber long axis steady-state-free-precession (SSFP) movie. The seven short 
axis tomographic slices were positioned starting from the level of the aortic valve. 
Slice thickness was chosen so that the seven slices would cover the entire left 
ventricle from apex to base. Since the duration of the 30 minute ischemia was 
insufficient to cover the entire LV, based on the anatomic position of the ligature of 
LAD only one of these seven slices was chosen to determine R1. Cine MRI, however, 
was acquired covering the entire LV. 
Normalized ∆R1 mapping 
An IR prepared segmented fast gradient echo sequence was used on a 1.5 
Tesla GE Signa Horizon CV instrument to determine R1. R1 values were obtained 
using the IR method employing eight different TI values. Short axis IR images were 
obtained with the following parameters: 260 mm FOV, 256x256 image matrix, 25° 
read out flip angle, 3.32 ms echo time (TE). TR was determined by the actual heart 
rate (TR=3 cardiac cycles). The acquisition of all TIs was timed to end-diastolic phase 
of the cardiac cycle. 
The R1 values for each region of interest (ROI) were calculated by curve 
fitting from the TI-dependent signal intensities using Equation 2 (60): 
SI = SIo (1 - A·e-TI·R1 + e-TR·R1)   (Eq 2) 
Where SI stands for observed signal intensity, SI0 for signal intensity at equilibrium, 
TI for inversion time, TR for repetition time, and A is a parameter (A≤ 2) obtained by 
the curve fitting procedure. The rightmost exponential term corrects for signal 
saturation (60). 
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Two alternative post-acquisition calculations with two different spacial 
resolutions were both carried out: a) R1 values were calculated for each myocardial 
sector serving as ROI according to the physical sectors in which myocardial perfusion 
was determined using microspheres; and b) R1 values were also calculated with a 
voxel-by-voxel resolution (each voxel as an ROI) exploiting the maximum spatial 
resolution potential provided by the equipment and the imaging pulse sequence. 
Myocardial Function 
To determine myocardial function, cine MRI images were acquired using an 
SSFP sequence. The applied parameters were: 260 mm FOV, 128x128 image matrix, 
45 ° flip angle. 
Image Analysis 
MR Analytical Software System (MASS) Version 5.0 (Medis, Leiden, 
Netherlands) running on a HP Pavilion 9600 PC was used for image analysis. The 
entire image set of a single study was scaled and windowed simultaneously. The 
corresponding signal intensity values of a set of IR images with varying TIs were used 
to determine R1 values of the myocardial ROIs. Myocardial function was determined 
using data calculated from SSFP movies. Following the localization of the 
centerpoint, the endo- and epicardial contours of the LV muscle in the short axis 
images were detected and manually readjusted. A 0o starting point at the postero-
septal groove is set for each individual image in the set. Following these initial 
settings, the software divided the mass of the LV muscle into 16 segments where each 
individual segment was perpendicular to the centerline.  
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Function and ∆R1 Data Analysis:  
The MASS program calculated cardiac function data, such as the difference 
between the end systolic and end diastolic wall thickness, wall thickening (WT); and 
the displacement of the end-systolic endocardial contour, wall motion (WM). Signal 
intensity (SI) data for each ROI were also measured using MASS. WT and MRI SI 
data were derived from the same myocardial volume elements. Corresponding data 
tables of WT and SI were then generated for the entire image set and processed. An 
R1 value was calculated for each individual ROI, thus generating an R1 map. An R1 
enhancement (∆R1ca) as defined by Eq 3, induced by CA in a given pixel, is 
proportional to the concentration of the CA in the voxel represented by that pixel.  
 ∆R1ca ~ R10 • [CA]     (Eq 3) 
Where R10 is the precontrast R1. This concentration is perfusion dependent, and thus 
the ∆R1 value of a given pixel is proportional to the perfusion in its voxel. The 
observed relaxation rate (R1obs) of a given pixel in the presence of the CA is the sum 
of the control relaxation rate R10 obtained in the absence of the CA and the relaxation 
rate enhancement ∆R1ca induced by the CA. Therefore, 
∆R1ca = R1obs–R10     (Eq 4) 
In comparison with corresponding MP values, sectors with ∆R1 less than or equal to 
0.8 s-1 were considered representing ischemic ROIs (∆R1cai). Thus, sectors with ∆R1 
values larger than 0.8 s-1 represented non-ischemic, remote sectors (∆R1car). 
To eliminate differences in R1 data among the individual dogs due to potential 
differences in effective contrast agent tissue uptake, all ∆R1 values were normalized 
to the average of the ∆R1 values observed in the non-ischemic areas (∆R1car) in each 
individual dog.  
∆R1n=∆R1cai/[∆R1car]     Eq(5) 
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The calculated values were compiled as a function of anatomical position. These 
normalized ∆R1n data from all ROIs in a given dog constitute the R1-enhancement 
map (∆R1n) which represents the myocardial perfusion distribution.  
Regional Function Analysis:  
A regional function map corresponding to the ∆R1n map was generated. 
Myocardial function of each individual sector was also compared to the 
corresponding myocardial perfusion and ∆R1n data. 
Pixel-by-pixel Image Analysis:  
To determine the ∆R1n values in the myocardium with a higher spatial 
resolution, a series of eight superimposable 60 pixel by 60 pixel image sections, 
containing the LV, was selected from the MRI images acquired with the eight 
different TIs. An automated algorithm was applied to determine the R1 value in each 
voxel associated with each pixel, using Equation 2. 
Perfusion Map:  
The relaxation rate, consequently the ∆R1n, of a given pixel is proportional to 
the concentration of the CA. This concentration is perfusion dependent, and thus the 
∆R1n value of a given pixel is proportional to the perfusion. Based on this correlation, 
the pixel-by-pixel ∆R1n map can be transformed into a pixel-by-pixel perfusion map 
(PM). 
Percent Perfusion Map (PPM):  
To establish a scale to convert ∆R1n values to perfusion values, the pixel with 
the maximum ∆R1n value (∆R1nmax) in that myocardium is sought. To calculate the 
exact percent perfusion value in each individual voxel, the following derivation 
applies: 
∆R1 nmax ~ Perfusionmax 
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Figure 4 Average ∆R1 values of the ischemic and 
non-ischemic sectors normalized to theR1 values 
measured during the control period in the
corresponding sectors.  
∆R1nmin ~ Perfusionmin     (Eq 6) 
∆R1n ~ Perfusion 
∆R1n / ∆R1nmax = Perfusion / Perfusionmax 
Perfusion = (∆R1n / ∆R1nmax) • Perfusionmax  (Eq 7) 
Thus, to express the perfusion in any given voxel as a percent of the maximum 
perfusion in a particular LV, a Percent Perfusion (PP) parameter is calculated from Eq 
5: 
 PP = (∆R1n/∆R1nmax) • 100    (Eq 8) 
The matrix containing the PP values of all voxels then yields the Percent Perfusion 
Map (PPM). 
Statistical analysis 
 Data were analyzed using SigmaStat version 3.0 (SPSS, Inc). Details of the 
statistical analysis for each type of results are given in the Results section. 
 
5.3 RESULTS 
In Figure 4 are depicted the mean ± standard error of ∆R1n values calculated 
in ischemic (n=47) and non-
ischemic sectors (n=94) of the 
eleven dogs. Using normalized 
∆R1 values (see METHODS 
section) all the ∆R1n values 
obtained in the 11 dogs were 
made animal-independent and 
thus comparable. Following CA 
administration, during the 
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Figure 5 A representative LV images in a single slice from one dog, 
acquired with a series of eight TIs varying from 150 to 1100 ms. 
Arrows point to the edges of the ischemic region. The ischemic region
is labeled with a black or white “i”. 
ischemia period a significant ∆R1n difference was found between the ischemic and 
non-ischemic ROIs by using Mann-Whitney Rank test (p < 0.001). Upon reperfusion, 
the difference not only decreased, but due to likely hyperemia and a consequently 
higher CA concentration in the previously ischemic myocardium, the ∆R1n value 
increased in these areas compared to the non-ischemic areas. This difference, 
however, was not significant.  
A typical image 
set from which ∆R1n 
values were obtained is 
shown in Figure 5. These 
images of a single LV 
tomographic slice were 
acquired with the eight 
different TIs. In images 
acquired with TIs below 
the contrast reversal point, 
reverse contrast is 
observed between the well 
perfused and ischemic 
regions; the ischemic region is brighter than the non-ischemic regions. The minimum 
signal intensities occurred around 400 ms for both the ischemic and non-ischemic 
regions. At TIs above 400 ms, the contrast becomes positive, i.e. the ischemic region 
is darker and the well-perfused region is brighter. The maximum contrast is 
observable in images acquired with TIs between 600 and 900 ms. 
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In Figure 6 the ∆R1n, WT and WM maps of the same single tomographic slice 
from one of the dogs are shown along with the corresponding MP. To illustrate the 
correspondence among the ∆R1n map, myocardial perfusion, and the two myocardial 
function maps, similar colors were used for all four parameters (Fig.6).  
 
Figure 6 Each rosette illustrates one of the maps: ∆R1, MP, WT, and WM, as a
function of the position of a given myocardial sector. Similar colors for all
parameters were applied to emphasize the correspondence among the
parameters.  
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Figure 7 Average values of MP and ∆R1n during 
ischemia are shown. The error bars indicate the
standard error of the mean calculated by using the
total number of ischemic and non-ischemic sectors.   
 
Figure 8 Normalized ∆R1 as a function of MP in all ischemic  
sectors evaluated in eleven dogs. The regression line was  
y = 82.27x + 0.04. 
In Fig. 7 bar graphs of the ∆R1n 
values in ischemic and non-
ischemic sectors from all dogs are 
compared with the corresponding 
MP bars. Mann-Whitney Rank 
test was used to determine the 
displayed p values of this 
comparison.  
In Figure 8 the ∆R1n data 
measured in the ischemic sectors 
of the 11 dogs are plotted as a 
function of the MP values in the 
corresponding sectors. The 
correlation coefficient calculated by using Pearson’s Product Moment Correlation is 
0.694 (p<0.005). Based on the correlation between ∆R1n and MP the myocardial 
perfusion is calculated 
from the ∆R1n values. 
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Figure 9 (A) The calculated pixel-by-
pixel ∆R1n map of the LV. The arrows
indicate the edges of the ischemic
zone. Figure 9 (B) The 
corresponding calculated pixel-by-
pixel PPM. The arrows indicate the
edges of the ischemic zone. 
 
A 
B 
In Fig. 9A, the potential of the method is 
demonstrated by a pixel-by-pixel 
resolved ∆R1n map of a single 
tomographic slice. Based on validation 
of the correlation between ∆R1n and MP, 
a pixel-by-pixel Percent Perfusion Map 
has been calculated in the same slice, and 
is shown in Figure 9B. 
Wall thickening (WT) and wall 
motion (WM) measured in the ischemic 
and non-ischemic sectors are shown 
along with the corresponding ∆R1n and 
MP values in Figure 10.    
Pairwise correlations were determined 
between ∆R1n and WT, ∆R1n and WM, 
and ∆R1n and MP in all ischemic sectors 
evaluated in eleven dogs using Pearson’s 
Product Moment Correlation. The 
correlation coefficients are compiled in Table 3. 
 
Table 3. The pairwise correlation between ∆R1n, MP, WT, and WM values from all 
ischemic sectors evaluated in eleven dogs. The statistical parameters here were 
obtained by Pearson’s Product Moment Correlation. 
 
Parameters Correlation coefficient (R) p value 
∆R1n vs. MP 0.694 P<0.005 
∆R1n vs. WT 0.534 P<0.005 
∆R1n vs. WM 0.529 P<0.005 
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Figure10 Average values of ∆R1n and Wall Motion (A), MP and Wall Motion (B), 
∆R1n and Wall Thickening (C), and MP and Wall Thickening (D), are shown. The
error bars indicate the standard error of the mean calculated by using the total
number of ischemic and non-ischemic sectors from all eleven dogs.    
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5.4 CONCLUSIONS  
 
The present study demonstrates the usefulness of normalized ∆R1 mapping 
using Gd(ABE-DTTA) for measuring myocardial perfusion and thus quantitatively 
delineating the ischemic regions in vivo. The ∆R1n map reflects the distribution of the 
CA concentration in the myocardium, and thus it is able not only to visualize, but also 
to quantify, the extent of ischemia in the myocardium. ∆R1n mapping visualizes R1 
increases induced by a CA more effectively than the usual T1-weighted signal 
intensity images. Such mapping, however, requires a contrast agent with a myocardial 
life-time long enough to allow the relatively long acquisitions needed for accurate 
determination of R1. Gd(ABE-DTTA) is a contrast agent whose sufficiently long 
myocardial lifetime maintains agent concentration practically unchanged in the course 
of a complete set of R1 acquisition. Thus using this agent it is possible to generate an 
accurate R1 map in a canine model of acute myocardial ischemia. 
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6. USING THE SAME METHOD IN A DIFFERENT DISEASE: VIRTUAL 
in vivo BIOPSY MAP OF EARLY PROSTATE NEOPLASM IN TRAMP 
MICE 
 
6.1 INTRODUCTION 
Prostate cancer (PC) is a commonly diagnosed cancer and the second leading 
cause of death in North American men.(41,42) Detecting prostate neoplasia early and 
providing the  availability of improved prognostic tools are crucial for reducing 
morbidity and mortality from PC.(42)  
In its initiation phase, PC is uniquely recognized as slow growing.(43-45) 
Autopsy studies have revealed that about 15-30% of males over the age of 45-50 have 
histological evidence of prostate cancer. Only in a small percentage PC becomes 
clinically manifest with age. PC fatalities are rarely due to primary tumors, but rather 
to widespread metastatic disease. Epithelial carcinogenesis proceeds via multiple 
steps of molecular and cellular alterations. These events can be separated into three 
distinct phases: initiation, promotion and progression. Mechanisms that trigger the 
progression of slowly growing, localized prostate tumors to a more aggressive form, 
and metastasis to distant organs, are poorly understood.(46) In our previous study, 
using MRI imaging, we showed that the expression of mutant p53 in the prostate 
increased the rate at which prostate tumors, initiated by SV40 Tag, progress to poorly 
differentiated adenocarcinoma.(47) The lack of reliable methods to track the 
progression of prostate cancer in vivo may be one reason for the lack of effective 
preventive and therapeutic modalities, or chemopreventive strategies for advanced 
PC.   
Numerous prognostic markers have been developed to detect PC. Due to its 
controversial diagnostic value, Prostate Specific Antigen (PSA) can no longer be 
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considered a reliable marker of PC in its early phase. (48) (49) A new hope among 
biomolecular diagnostic tools is proteomic pattern analysis. (50) Such types of 
molecular profiling of PC, however, are still in their infancy. As with any emerging 
technology, many limitations must be overcome before it can be applied to clinical 
practice.(42) To date, none of these markers can reliably detect PC in the early phase.  
Prostate Intraepithelial Neoplasia (PIN) is precancerous neoplasia of the 
prostate. It exists as early lesion of prostate and is well defined in TRAMP mice. In 
humans, PIN has recently become recognized as of paramount, early, predictive 
importance for PC, as aptly summarized by D.G. Bostwick (51) stating that PIN is the 
most likely preinvasive stage before adenocarcinoma with a high predictive value as a 
marker, and that most patients with PIN will develop carcinoma within 10 years. 
A noninvasive method, like MRI, for the detection of such an early marker 
would be highly desirable. To date, however, there is no consensus in the field with 
regard to an appropriate MRI method for the staging of PC. Some favor 
MRI/MRS,(52) some favor DCE MRI, over other imaging techniques. Hara et al. 
successfully used Dynamic Contrast Enhanced (DCE) MRI to stage prostate cancer. 
(53) (54) In their study, however, they seemed to have investigated only tumors larger 
than 1 cm and the histological state of the tumor was not earlier than well 
differentiated adenocarcinoma. Moreover, this study was done on large hypertrophic 
prostates. As to the present state of the art of early-phase MRI diagnosis of PC, a 
number of investigators have questioned the usefulness of MRI: Storaas et al. could 
not find statistically significant advantages for tumor localization adding DCE MRI 
information to that obtained by T2-weighted images.(55) Allen et al could not detect 
microscopic lesions in patients with low risk, using MRI equipped with a body 
coil.(56) Ikonen et al. found the detection rate by MRI of prostate tumors smaller than 
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5 mm to be less than 10%.(57)  Note, that all the above studies investigated PC in its 
adenocarcinoma phase. Visualization of PIN in humans with MRI or with any other 
imaging method has yet to be carried out.(51)    
All these MRI efforts to date have been based on signal intensity (SI) images. 
In contrast enhanced MRI (ceMRI) the images show tissue differentiation, when they 
do, on the basis of signal intensity enhancement (SIE). SIE in ceMRI is dependent on 
contrast agent concentration in the prostate tissue volume element (voxel) represented 
by the image area in question, but not in a linear fashion. SI is not an intrinsic 
parameter, rather it is also dependent on the pulse sequence and acquisition 
parameters used. Another confounding factor is the inhomogeneity caused by the MRI 
coil, artificially imparting varying SIs to different parts of the prostate depending on 
their relative position to the coil. The intrinsic physical parameter which is enhanced 
in linear proportion with contrast agent concentration is the paramagnetic ∆R1 (∆R1p) 
(longitudinal relaxation rate enhancement), induced by a contrast agent.(4) The ∆R1p 
of a given prostate tissue volume element actually represents the ∆R1p value 
integrated over that volume element, because the ∆R1, contrary to MRI SI 
parameters, is additive. Thus, a three dimensional (3D) R1 map of the prostate is a 
faithful representation of contrast agent distribution with the same in-plane resolution 
as of a regular image and with the slice thickness determining the resolution in the 
third dimension.  
Our results indicate that the contrast agent Gd(ABE-DTTA) (58) is distributed 
in the prostate in the TRAMP mouse model in inverse proportion to the tissue’s 
neoplastic content. It is quite evident from the state of the art that a yet nonexistent, 
noninvasive imaging method for repeat monitoring of PIN is highly desirable and 
timely. We wish to suggest such a method, ceMRI combined with our contrast agent, 
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Gd(ABE-DTTA), using a particularly useful method of image analysis, R1 mapping. 
In our study in twelve TRAMP and three control mice, we have shown that prostate 
tissue with early high-grade PIN and/or still well-differentiated adenocarcinoma 
(WD) can be distinguished by our method from normal tissue and/or low-grade PIN. 
The results presented here suggest a potential method for future clinical use. 
 
6.2 METHODS  
Through a concerted effort in several laboratories, Greenberg et al (61) (62) 
(63,64) established a transgenic mouse model of PC, TRAMP (TRAnsgenic Mouse 
Prostate adenocarcinoma). TRAMP mice were generated with the SV40 small and 
large T antigen (Tag) regulated by the rat probasin gene promoter. Since probasin is a 
prostate-specific protein, this provides targeted expression of Tag in the prostate, 
resulting in transgene expression spatially restricted to the prostate. Expression 
correlates with sexual maturity and is hormonally regulated by androgens. TRAMP 
mice display progressive forms of prostate carcinoma, with development of 
premalignant lesions, mouse prostate intraepithelial neoplasia (PIN), carcinoma in 
situ, local advancement into lymphatics, metastatic disease and androgen receptor 
resistance (61) (62) (63,64). Many of the biological variables that drive prostate 
growth and invasion have been identified in this mouse. Originally, TRAMP mice had 
been kindly provided by Dr. Greenberg (Baylor College of Medicine, Houston) to one 
of our authors, Dr. Ada Elgavish, who then established a colony of TRAMP mice at 
the UAB. In our study, the TRAMP mouse model was used to investigate the 
detection of PIN, the early, precancerous form of prostate cancer.  
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Contrast Agent (Gd(ABE-DTTA) 
The contrast agent Gd(ABE-DTTA) was synthesized and sample preparation 
was carried out as described above on page 19.  
Anesthesia and Contrast Agent Administration Prior to MRI Sessions 
Mice were initially anesthetized using 0.15 vol% Isoflurane. The tail vein was 
punctured and Gd(ABE-DTTA) was administered at a dose of 0.05 µmol per gram 
body weight. Anesthesia was continued at the reduced dose of 0.12 vol% Isoflurane. 
The mouse then was placed in the MRI coil. Body temperature was maintained by a 
custom made electric heat blower attached to a conduit. 
MRI  
A 4.7T Bruker MRI scanner was used, equipped with a 78 mm diameter body 
coil. Following the initial setup (tuning, shimming, receiver gain setting, etc.), a quick 
T2-weighted image set was acquired to determine the position of the prostate. Once 
done, a single 2 mm thick tomographic slice, containing the entire organ and typically 
close to the coronal orientation with the urethra in the center, was oriented through the 
prostate. This slice was used to acquire the R1 map for the entire prostate volume. A 
Multi-Slice Multi-Echo (MSME) inversion recovery (IR) sequence was used for 
acquisition of R1 maps with the following parameters: FOV: 5 cm, matrix: 128·128, 
voxel size: 0.39mm·0.39mm·2mm, number of slices: 1, recycle time (TR): 3000 ms, 
inversion times (TI): 60, 100, 200, 300, 600, 800, and 1000 ms. At the end of the MRI 
session the mouse, still anesthetized, was euthanized using a mixture of ketamine and 
xylazine overdose followed by cervical dislocation. 
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R1 map: 
The part of the image that contains both lobes of the prostate (an 
approximately 2.4cmx2.4cm square out of the 5cmx5cm field of view) was selected 
as region of interest (ROI) for analysis. This square constituted a 60 pixel by 60 pixel 
matrix.  Since all the images of a given stack were acquired within the exact same 
slice and with the position of this ROI remaining constant, the eight images in a stack 
were of identical registration. Thus the only parameter varied among these eight 
images was the TI. 
The R1 value of each pixel in the 60x60 pixel matrix was calculated from the 
SI vs. TI dependence, applying a three-parameter least-squares curve fitting routine, 
using the following formula (60) 
SI = SIo · (1 - A·e-TI·R1)      Eq 1 
where SI is the signal intensity obtained with a given TI, SI0 is the signal intensity at 
equilibrium, and A is a constant which in the absence of saturation and under other 
ideal conditions would equal 2.0. 
The R1 value in each pixel was calculated from the SI vs. TI dependence as 
shown above. A good image quality, necessary for accurate R1 determinations, as 
well as a good coregistration of all images within the same stack, was confirmed by 
the correlation coefficient (R2).  
R1 values estimated from SI values acquired with only two or three inversion 
delays are not as accurate as those measured with the eight TI inversion recovery (IR) 
set, which, however, is time consuming. A fast sequence approach has been recently 
demonstrated by Messroghli et al., showing the feasibility of fast IR-based R1 
mapping of the heart in patients (65). Using such a technique in prostate MRI, once 
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the technique becomes commercially available, the time needed to acquire a R1 map 
of the entire prostate can be reduced substantially.  
Normalized R1 Map and Neoplastic Index Map 
It is difficult to administer an exact reproducible dose of the contrast agent in 
each individual mouse. Therefore, to eliminate possible differences among animals, 
the R1 values measured in a prostate region have been normalized to the R1 value 
measured in the thigh muscle (R1norm) of the same animal. Following the 
administration of the contrast agent, we have observed that voxels with the lowest 
relaxivity (R1lo) in a given prostate correspond with prostate regions that contain the 
largest amount of tissue that has histology scores 3-4 (see METHODS section). 
Conversely, voxels with the highest relaxivity (R1hi) have been those that contain the 
least amount of tissue with scores 3-4. The relaxivity of any given voxel is thus 
governed by the relative proportions of tissue with scores 1-2 versus tissue with 
scores 3-4. Therefore the R1 value (R1v) measured in any given voxel (v) in the 
prostate will be found on an R1 scale that ranges between R1hi and R1lo. Thus the 
difference ∆v=R1hi-R1v reflects the extent of neoplasticity in that voxel. When 
R1v=R1hi, ∆v is zero, indicating no neoplasticity. When R1v=R1lo, ∆v obtains its 
maximum value, reflecting a fully neoplastic voxel. A percent neoplastic index (NIv) 
can be then calculated in every voxel v by normalizing ∆v with the maximum range; 
i.e.  R1hi-R1lo (Eq 2).  
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NIv will take the value of 100% when R1v=R1lo (maximum neoplasticity) and 
zero when R1v=R1hi (fully normal tissue). Thus, by calculating the NIv value for all 
voxels, the pixel-by-pixel R1 map of the prostate can be converted into a voxel-by-
voxel NI map reflecting quantitatively the neoplastic content of every given voxel in 
the map.  
Based on the NIv value of all prostate voxels in a given prostate, the total 
volume of the cells with score≥3 (Neoplastic Volume, NV) can be calculated from 
Eqation 3: 
∑
=
•=
n
1
NIVNV
v
vv         [Eq 3]  
Where Vv is the voxel volume and n is the number of prostate voxels.  
The NV values obtained from our experiments are compiled in Table 4. 
Histological Analysis 
Following euthanasia the urogenital tracts were excised en bloc, pinned to a 
small piece of plastic foam to avoid disintegration of the sample. An approximately 
4mm block was selected by recognizing and precisely following the urethra while 
slicing the urogenital tract ensuring that the entire prostate is contained in the physical 
block, corresponding to the tomographic slice. The slice was excised and further 
processed for histological analysis. It was frozen by immersing the block into 2-
methylbutane liquid previously cooled with dry ice. The block later on was cut 
through the urethra and 5 µm thick slices were taken for histological analysis. The 
histological sections were stained using the Gömöri-Trichrome method. In the 
microscopic slides, the areas of the histologically homogenous regions, recognizable 
on the R1 maps (as well as on the normalized R1 maps), were measured and their 
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histological scores were determined as described by Wechter et al. (66) Noncancerous 
tissues were scored 1, 2, or 3, indicating healthy, low-grade PIN and high-grade PIN, 
respectively. Scores 4 indicated well-differentiated adenocarcinomas (66). In our mice 
only scant areas of poorly differentiated adenocarcinomas (score 5) were found and 
thus no appropriate statistics could be carried out on this type of tissue. Therefore, we 
have decided to exclude these areas from the study.  
All areas of tissue regions with the same histological score were measured in 
the postmortem histological sections. Corresponding areas in the calculated R1, 
normalized R1, and Neoplastic Index maps were also measured. For each region with 
a well-defined score, a fractional neoplastic area (neoplastic area/total prostate lobe 
area) was calculated both in the histological sections and in the R1 map. Other MRI 
related parameters (normalized R1, NI) measured in the corresponding regions were 
exported for further analysis. 
Statistical Analysis 
Statistical analysis of the data was carried out using SigmaStat version 2.03 
(SPSS, Inc). To compare two groups, Student’s t-test was used if data passed the test 
for normal distribution. To compare several groups, One way ANOVA (for one 
independent variable) or two-way ANOVA (for two independent variables) were 
used. Pearson’s correlation coefficient r was calculated to evaluate relationships. 
Rejecting the null hypothesis at α = 0.05 with a P-value < 0.05 was interpreted to 
indicate a significant difference.  
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Figure11 Inversion recovery MRI images acquired with
TI=800ms are shown during pre-contrast control (a), and
following Gd(ABE-DTTA) administration (b). LL, RL indicate left
and right lobe of the prostate, respectively and U labels the
urethra. 
Figure12 R1 maps are shown during control (a) and following
Gd(ABE-DTTA) administration (b). The thick arrows indicate the
lobes of the prostate. The black broken arrows indicate the dark (D)
and the white broken arrows point to the bright (B) prostate areas. 
6.3 RESULTS  
To demonstrate the effect 
of the contrast agent, one 
inversion recovery (IR) 
image (at TI=800 ms) of 
an axial tomographic slice 
that contains the prostate 
of a TRAMP mouse is 
shown in Fig.11. in the 
absence of (a), or in the 
presence of (b) Gd(ABE-
DTTA).  In the rest of 
the mice similar results 
were obtained. In Fig.12 
the corresponding R1 
maps, calculated from the 
image sets related to the image shown in Fig.11, are shown. Although in the regular 
contrast enhanced, IR images (Fig.11) the prostate lobes are sufficiently delineated, 
no differentiation between neoplastic and normal prostate tissue is visible. Nor is such 
differentiation obtained in the R1 map in the absence of agent (Fig.12a). In the 
Gd(ABE-DTTA)-enhanced R1 image (Fig.12b), however, darker versus brighter 
prostate areas are evident. As proven below by comparison with histology, this R1 
based differentiation in Fig.12b. corresponds to differentiation between score 3-4 
neoplastic tissue versus score 1-2 tissue. Thus from comparing Figs. 11 and 12, it is 
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evident that only a contrast-enhanced R1 image provides diagnostically valuable 
information in this case. R1 mapping provides the largest contrast between healthy 
prostate tissue versus tissue with high-grade PIN or adenocarcinoma (Fig. 13).  
 
Figure13 The calculated R1 map (I), the magnified section of  the prostate (II),
and the histological sections of the two lobes (III-left lobe, IV-right lobe) are 
shown. Normal (score 1), low grade PIN (score 2), high grade PIN (score 3) and 
well differentiated adenocarcinoma (score 4) can be identified. The white arrows
indicate the position of areas with different histological scores in the prostate
tissue.  
In Figure 13 the co-registration of the MRI delineated areas in the prostate 
lobes with the histological scores found in the corresponding physical prostate areas is 
shown. Wu et al (69) used three dimensional ultrasound to detect prostate tumors in 
TRAMP mice, but no staging of the tumors was carried out. Moreover, they couldn’t 
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Figure14 Fractional Neoplastic Areas detected by 
MRI (Y axis) and Histology (X axis). The good 
correlation (R=0.88) indicates that the areas detected 
by MRI correspond well to the areas detected by 
histology (P<0.001) 
detect PIN, but only well- or poorly differentiated adenocarcinoma. The smallest 
tumor detected was over 3.5 mm. (69) In our present study, prostate neoplasms 
smaller than 2 mm could be visualized, even when consisting of high-grade PIN only 
and no adenocarcinoma,. The fractional neoplastic area values (see METHODS) 
obtained from the histological sections were correlated pairwise with values obtained 
from their corresponding R1 map (Fig. 
14). 
R1 values from ROIs 
containing prostate tissue in the twelve 
TRAMP and three litter-mate 
nontransgenic controls were each 
individually normalized to the R1 in 
muscle tissue near the prostate of the 
same mouse to account for possible 
variations among the mice in contrast 
agent uptake. Mean R1(±STD) values 
corresponding to the histologically distinct areas were calculated first for each mouse 
separately and than averaged for all twelve TRAMP mice. Results were similarly 
calculated for the three control mice.  
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Figure15 Mean values of normalized R1 from TRAMP are shown  for normal &low-
grade PIN PRE- (1.03±0.04 s-1) (C), and POST-contrast agent administration (1.24±0.03 
s-1) (B), high-grade PIN &WD PRE- (1.01±0.02 s-1) (D), and POST-contrast (0.92±0.02 s-
1) (E), along with the overall prostate POST-contrast (1.20±0.01 s-1) from the three 
control mice (A). As expected, the post contrast values in the control mice and the
normal &low-grade PIN regions in TRAMP are practically indistinguishable, and display
substantially higher post-contrast than pre-contrast values, indicating that the contrast 
agent is taken up into normal &low-grade PIN prostate tissue but not high-grade PIN 
tissue.   
 
P<0.05 
P<0.05 
 
The overall R1 means are depicted in Figure 15 as bar graphs along with their 
corresponding STD values: normal&low-grade PIN PRE- (0.90±0.007 s-1) (C) and 
POST-contrast agent administration (1.25±0.18 s-1) (B), high-grade PIN&WD PRE- 
(0.88±0.02 s-1) (D), and POST-contrast (0.93±0.11 s-1) (E), along with the overall 
prostate POST-contrast from the three control mice (1.17±0.03 s-1) (A). As expected, 
the post-contrast values in the control mice and the normal&low-grade PIN regions in 
TRAMP mice are practically indistinguishable, and substantially higher than the pre-
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Figure16 The mean values of the Neoplastic Index (NI) 
shown separately for prostate regions with the different 
histologic scores. It is apparent that there is no 
statistical difference in NI between regions with scores 
1 and 2 (group A), or among regions with PIN 3 and 4 
(group B). There is, however,  a significant difference in 
NI  between regions from goup A versus regions from 
group B (p<0.005). 
P<0.05 
0
10
20
30
40
50
60
70
80
90
Scores 1-2 Scores 3-4
Histological Score
N
eo
pl
as
tic
 In
de
x
 Figure17 The mean values of the
Neoplastic Index found in prostate regions
with scores 1and 2 (group A) versus scores
3 and 4 (group B).  
 
contrast values, indicating that the contrast agent is taken up into normal&low-grade 
PIN prostate tissue and persists there for the entire duration of the MRI scanning. 
 
6.4 CONCLUSIONS 
Our results indicate that Gd(ABE-DTTA) 
is distributed in the prostate in inverse 
proportion to the tissue’s neoplastic 
content in the TRAMP mouse model. 
Thus, the R1 value of a given prostate 
volume element is governed by the 
fraction of neoplastic tissue of scores 3 
and 4 in that volume element.  
Therefore, our results seem to show that 
an R1 map made following the 
administration of Gd(ABE-DTTA) can 
differentiate normal prostate tissue 
(score 1) or low score (score 2) mouse 
prostatic intraepithelial neoplasia (PIN) 
from tissues with either high score PIN 
(score 3) or well differentiated 
adenocarcinoma (WD) (score 4) within the murine prostate lobes. It is worth 
emphasizing that these lobes are often less than 5 mm in diameter, yet such tissue 
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differentiation nevertheless has been possible with our technique. Early neoplasia 
(scores 3-4) in a given voxel can be identified by its reduced R1 enhancement 
compared to normal tissue where contrast-agent induced R1 enhancement is 
substantially greater.  
NI values (see METHODS Section) were also calculated pixel-by-pixel and 
were averaged in each prostate region. In Figure 16, the NI values measured in 
regions with different histological scores are shown. It is apparent that difference in 
NI from areas with score 1 versus those with score 2 does not rise to statistical 
significance. Similarly, the difference among the NI values from sectors with scores 3 
and 4 is also non-significant. Thus, in Figure 17 we show the average NI values 
measured in regions with score 1-2 combined, versus regions with scores 3 and 4 
combined. With the NI parameter, the difference between the two distinguishable 
groups of tissue areas is quite apparent. The average border value of NI for all 
TRAMP mice between these two groups was found to be 66.7±4.4 (see Table 4). 
Table 4. Total prostate volume, mean NI ( vNI ), NI border values, neoplastic volume 
values, acquired in the twelve TRAMP mice, are shown. The lowest NI values 
acquired in a region with a histological score 3 or above were considered NI border 
values.  
 
Prostate Volume 
(uL) 
 
 
NI Border 
Value 
Neoplastic Volume 
(uL) 
TRAMP 1 266 0.68 64 181 
TRAMP 2 120 0.70 69 84 
TRAMP 3 84 0.77 70 64 
TRAMP 4 80 0.75 64 60 
TRAMP 5 91 0.62 69 57 
TRAMP 6 313 0.68 68 213 
TRAMP 7 216 0.71 76 153 
TRAMP 8 275 0.57 62 157 
TRAMP 9 145 0.61 65 88 
TRAMP 10 124 0.71 61 88 
TRAMP 11 413 0.62 62 256 
TRAMP 12 157 0.70 65 109 
vNI
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As a conclusion, a non-invasive method, using R1 mapping in the presence of 
Gd(ABE-DTTA) could successfully be used to distinguish early phases of prostate 
neoplasm from its developed phases in TRAMP mice. 
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7 DISCUSSION 
In our work we managed to prove that Gd(ABE-DTTA) can successfully be 
used at high field to measure R1 and so, create R1 maps. The relaxivity of 
Gd(DTPA), the most often used contrast agent in the clinic, decreases with increasing 
field strength. Gd(ABE-DTTA), on the other hand, demonstrates a local maximum in 
relaxivity at a very high field strength, around 5T (Fig. 2B). As our results 
demonstrate, this agent can be used at any field strength between 1.5 and 10T without 
significant loss of efficacy. 
This attribute is particularly valuable in light of the increasing field strength, 
to achieve better signal-to-noise ratio, of the MRI machines used in the clinic. 
Addition to the above detailed field dependency profile, Gd(ABE-DTTA) has a 
particularly long life time in the blood and in the tissues that makes this contrast agent 
an optimal candidate to carry out R1 measurements on the MRI instruments that 
currently used in the clinic. 
 
As it was expected, in our myocardial ischemia canine experiments, based on 
the differential distribution of the CA in the ischemic vs. non-ischemic myocardium, 
the ∆R1n values were significantly lower in the ischemic regions than in the non-
ischemic areas during the ischemic period. During reperfusion, this difference 
vanished (Fig. 4). In the individual experiments the lower ∆R1 values showed 
regional correlation with the regional function parameters assessed by MRI (WT, 
WM), as well as with the MP values (Fig. 6). A good correspondence among the 
various maps is evident. The underperfused areas are clearly shown by the ∆R1n map. 
Good correspondence is observed between the location of the underperfused sectors 
defined by the ∆R1n map and that shown by the MP map, thus validating the former. 
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The difference between the average ∆R1n values measured in the ischemic vs. 
non-ischemic sectors is similar to that observed between the corresponding average 
MP values (Fig. 6). 
In our experiments the ischemic areas became clearly delineated. In these 
areas a close correlation was found between the ∆R1n and the MP values of the 
corresponding sectors (Fig. 7). A good correlation was observed between wall 
thickening and ∆R1n as well as the wall motion data versus ∆R1n, demonstrating 
accurate localization of the ischemic regions by ∆R1n mapping.  
We have shown the extent to which the ∆R1n values obtained after the 
injection of Gd(ABE-DTTA) reflect the myocardial perfusion. Once the correlation 
between MP and ∆R1n has been established, a pixel-by-pixel ∆R1n map (Fig. 8A) can 
be translated into a PP map with the same resolution (Fig. 8B). It is worth mentioning 
that with this method the spatial resolution is higher than even in the post mortem 
gold standard set by the microsphere determination of MP, the resolution of which is 
about 1 cm3. Using the ∆R1n map, however, each ∆R1n value leading to the perfusion 
map can be obtained from a 0.014 cm3 tomographic volume of the myocardium. 
Using a color scale spread between the minimum and maximum values found in the 
slice, the perfusion in each pixel in this calculated map can be clearly presented. The 
basis for these correlations is the fact that voxels with high perfusion values possess 
high CA concentrations, and consequently high ∆R1n values.  
Analyzing the average results of the different parameters in Figure 9, one can 
observe that both WT and WM show roughly proportional difference between the 
ischemic and non-ischemic sectors similar to those displayed by ∆R1n and MP. As 
indicated by the p values (Table 1), a significant correlation was observed between 
 51
∆R1n and myocardial perfusion, as well as between each of the two function 
parameters and ∆R1n. 
In clinical practice there has been a growing need for accurate and non-
invasive determination of acute myocardial perfusion defects. Based on its 
sufficiently long myocardial lifetime, Gd(ABE-DTTA) is suitable to serve as a 
cardiac CA, that in conjunction with an ∆R1n map can provide quantitative 
information about myocardial perfusion in ischemia. 
 
With using our contrast agent and method (R1 mapping) we studied a model 
of a completely different disease, prostate neoplasm, to see if they can be used in the 
diagnostics of such disease as well. In the TRAMP mice experiments similar results 
were found.  
The post-contrast mean, normalized R1 obtained from regions with high-grade 
PIN &WD, however, are not different from the pre-contrast mean. This suggests that 
high-grade PIN and WD regions did not take up Gd(ABE-DTTA), contrary to the 
normal&low-grade PIN regions. This indicates that a possible mechanism underlying 
the Gd(ABE-DTTA)-aided R1 differentiation between WD and early neoplasm (high-
grade PIN) versus normal or low-grade PIN prostate tissue may be an abnormal 
vasculature in the neoplastic prostate areas. Such prostate vasculature has been 
reported by Ozawa et al. (74). Abnormal vasculature may reduce the access of the 
contrast agent to the high-grade PIN areas for the same reason that chemotherapeutic 
agents often fail to be taken up in tumors. (75) 
Our results are inconsistent with the findings in human studies (53) where the 
post contrast MRI signal intensities were found to be higher in the cancerous areas 
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than in the normal prostate areas. Our results can be well understood, however, in 
light of the studies by Jain et al. (75). They have shown that in tumors during 
angiogenic development within a certain “time window”, the imbalance of the pro- 
and anti-angiogenic (thrombobospodin-1 and VEGF, respectively) factors makes 
tissue blood circulation impaired due to formation of abnormal vasculature. The 
endothelial cells display aberrant morphology, pericytes are loosely attached or often 
absent, the basement membrane is also abnormal, either abnormally thick or absent. 
These factors lead to impaired perfusion in the tumor tissue resulting in abnormal 
tumor microenvironment. The hydrostatic pressure is elevated outside the blood 
vessel due to hypoxia and acidosis. This elevated pressure further diminishes the 
perfusion of the neoplastic tissues. Nevertheless, the cancer cells unfortunately can 
survive in such pathological microenvironment (75). Jain et al thus have suggested a 
new approach in cancer treatment by restoring the tumor vasculature to normal before 
chemotherapy by administering anti-angiogenic factors in the right period at a proper 
(they suggest low) dose, making the treatment more effective.(75) In short, the 
extensive work of Jain et al. makes our results relevant within the right period in 
neoplastic development while point to the possibility that human MRI studies were 
inadvertently carried out in a different time window.  
In summary, our method is equivalent to a post-mortem biopsy examining the 
entire prostate, yet done noninvasively. Therefore, our method yields an in-vivo-
obtained virtual biopsy map (VBM) (Figures 18 and 19). In this manner the 3D 
information inherent in MRI images can be used to quantify the extent of neoplasm. 
Thus, using VBM, as the only noninvasive method to date in the early phase of PC 
development, high-grade PIN areas and/or WD areas can be visualized in 3D with 
relatively high sensitivity and resolution. The practical resolution of VBM reaches 
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Figure18 A three-dimensional virtual biopsy map acquired from the prostate
tissues of a TRAMP mouse is shown. The highest peaks highlighted with red 
color are the voxels with the maximum amount of tissue with scores 3 and 4. The
left hand area corresponds to area III of Fig. 13, and the right hand area 
corresponds to area IV of Fig. 13. 
 
that of the MRI acquisition itself, which is higher than that of the presently used 
imaging techniques combined with biopsy.(76) 
It is now well established that, in humans as well, PIN progresses to 
adenocarcinoma (77). Thus, detection of PIN could become tantamount to early 
detection of PC. 
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Determination of NI can be utilized to predict the emergence of poorly 
differentiated adenocarcinoma. A high-resolution virtual biopsy map, based on this 
parameter, could become in the future a useful tool for clinicians in diagnosis of 
cancer of the prostate and possibly of other organs. 
Figure19 A two-dimensional virtual biopsy map of the prostate acquired in a 
TRAMP mouse is shown. The red color indicates the voxels that contain the
maximum amount of tissue with scores 3-4. This figure is the 2D projection of the 
information in Figure 18. 
 
 In conclusion, in our work we have proven in models of multiple diseases that 
using a contrast agent with a sufficiently long half-life and with a preserved relaxivity 
in the high field, R1 map can provide more, quantitative and reproducible information 
to the clinicians.  
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8 NEW FINDINGS 
 
8.1 A unique field dependency of Gd(ABE-DTTA) was found; unlike most of the 
commercially available MRI contrast agents, Gd(ABE-DTTA) showed a maximum 
relaxivity enhancement at around 5T. This makes it suitable for using it on high field. 
This is an important finding considering the recent trend of the MRI instruments’ field 
strength. 
 
8.2 Many of the imperfections of the SI based perfusion detection in the 
myocardium are mostly due to the single image method itself, such as field 
inhomogenity, coil effects, etc. R1 measurements, however, can eliminate most of 
these effects. Presently, on most of the MRI instruments, the duration of an R1 
measurement exceeds the half life of the commercially available contrast agents. 
Gd(ABE-DTTA) has a half life in the blood long enough to acquire such parameter in 
its present. It has successfully been used in a myocardial ischemia-reperfusion canine 
model to quantitatively and reproducibly detect myocardial ischemia on a voxel-by-
voxel manner.  
 
8.3 Most of the presently known MRI methods to detect human prostate neoplasm 
can only visualize prostate cancer in its developed phase. Using our contrast agent and 
the same method we successfully could detect TRAMP mouse prostate intraepithelial 
neoplasm in its early phase; we could distinguish mouse prostate voxels with mPIN 
score 1-2 from voxels with score 3 and above.  
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